BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 32932351)

  • 1. Effect of Renin-Angiotensin-Aldosterone System Blockade on Long-Term Outcomes in Postacute Kidney Injury Patients With Hypertension.
    Yang CY; Liu JS; Tseng WC; Tsai MT; Lin MH; Kao ZK; Lin YP; Hsu CC; Tarng DC
    Crit Care Med; 2020 Dec; 48(12):e1185-e1193. PubMed ID: 32932351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
    Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
    JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kidney Function and Potassium Monitoring After Initiation of Renin-Angiotensin-Aldosterone System Blockade Therapy and Outcomes in 2 North American Populations.
    Parikh RV; Nash DM; Brimble KS; Markle-Reid M; Tan TC; McArthur E; Khoshniat-Rad F; Sood MM; Zheng S; Pravoverov L; Nesrallah GE; Garg AX; Go AS
    Circ Cardiovasc Qual Outcomes; 2020 Sep; 13(9):e006415. PubMed ID: 32873054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of dual compared to no or single renin-angiotensin system blockade on risk of renal replacement therapy or death in predialysis patients: PREPARE-2 study.
    Voskamp PWM; Dekker FW; van Diepen M; Hoogeveen EK;
    J Am Soc Hypertens; 2017 Oct; 11(10):635-643. PubMed ID: 28802945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective Cohort Study of Renin-Angiotensin System Blocker Usage after Hospitalized Acute Kidney Injury.
    Brar S; Liu KD; Go AS; Hsu RK; Chinchilli VM; Coca SG; Garg AX; Himmelfarb J; Ikizler TA; Kaufman J; Kimmel PL; Parikh CR; Siew ED; Ware LB; Zeng H; Hsu CY; ;
    Clin J Am Soc Nephrol; 2020 Dec; 16(1):26-36. PubMed ID: 33272913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.
    Lin CC; Wu YT; Yang WC; Tsai MJ; Liu JS; Yang CY; Li SY; Ou SM; Tarng DC; Hsu CC
    PLoS One; 2017; 12(12):e0189126. PubMed ID: 29216260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renin-Angiotensin System Blockade after Acute Kidney Injury (AKI) and Risk of Recurrent AKI.
    Hsu CY; Liu KD; Yang J; Glidden DV; Tan TC; Pravoverov L; Zheng S; Go AS
    Clin J Am Soc Nephrol; 2020 Jan; 15(1):26-34. PubMed ID: 31843974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in dialysis patients: a nationwide data survey and propensity analysis.
    Wu CK; Yang YH; Juang JJ; Wang YC; Tsai CT; Lai LP; Hwang JJ; Chiang FT; Chen PC; Lin JL; Lin LY
    Medicine (Baltimore); 2015 Jan; 94(3):e424. PubMed ID: 25621694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With Outcomes After Acute Kidney Injury.
    Brar S; Ye F; James MT; Hemmelgarn B; Klarenbach S; Pannu N;
    JAMA Intern Med; 2018 Dec; 178(12):1681-1690. PubMed ID: 30422153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study.
    Fu EL; Clase CM; Evans M; Lindholm B; Rotmans JI; Dekker FW; van Diepen M; Carrero JJ
    Am J Kidney Dis; 2021 May; 77(5):719-729.e1. PubMed ID: 33246024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
    Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
    Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renin-angiotensin system blockade in heart failure patients on long-term haemodialysis in Taiwan.
    Tang CH; Chen TH; Wang CC; Hong CY; Huang KC; Sue YM
    Eur J Heart Fail; 2013 Oct; 15(10):1194-202. PubMed ID: 23671265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Antihypertensive Agents and Association With Risk of Adverse Outcomes in Chronic Kidney Disease: Focus on Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers.
    Ku E; McCulloch CE; Vittinghoff E; Lin F; Johansen KL
    J Am Heart Assoc; 2018 Oct; 7(19):e009992. PubMed ID: 30371331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate.
    Qiao Y; Shin JI; Chen TK; Inker LA; Coresh J; Alexander GC; Jackson JW; Chang AR; Grams ME
    JAMA Intern Med; 2020 May; 180(5):718-726. PubMed ID: 32150237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: Systematic review and meta-analysis.
    Salvador GL; Marmentini VM; Cosmo WR; Junior EL
    Eur J Prev Cardiol; 2017 Dec; 24(18):1914-1924. PubMed ID: 28862020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and the risk of major adverse cardiac events in patients with diabetes and prior stroke: a nationwide study.
    Shih CJ; Chen HT; Chao PW; Kuo SC; Li SY; Yang CY; Tarng DC; Ou SM; Chen YT
    J Hypertens; 2016 Mar; 34(3):567-74; discussion 575. PubMed ID: 26703918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Renin-angiotensin-aldosterone System Inhibitors With Coronavirus Disease 2019 (COVID-19)- Related Outcomes in Korea: A Nationwide Population-based Cohort Study.
    Jung SY; Choi JC; You SH; Kim WY
    Clin Infect Dis; 2020 Nov; 71(16):2121-2128. PubMed ID: 32442285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast Growth Factor-23, Heart Failure Risk, and Renin-Angiotensin-Aldosterone-System Blockade in Hypertension: The MESA Study.
    Akhabue E; Vu TT; Vaidya A; Michos ED; de Boer IH; Kestenbaum B; Allison M; Szklo M; Ouyang P; Yancy CW; Wolf M; Isakova T; Carnethon MR
    Am J Hypertens; 2019 Jan; 32(1):18-25. PubMed ID: 30256890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. End-stage renal disease patients using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may reduce the risk of mortality: a Taiwanese Nationwide cohort study.
    Lee HF; See LC; Chan YH; Yeh YH; Wu LS; Liu JR; Tu HT; Wang CL; Kuo CT; Chang SH
    Intern Med J; 2018 Sep; 48(9):1123-1132. PubMed ID: 29808610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.